SCHEMBL360646

SCHEMBL360646

COC(=O)c1nccnc1C(=O)CC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.39
ATR Q13535 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
CCNB2 O95067 1/20 0.34
CCNE2 O96020 1/20 0.34
CDK1 P06493 1/20 0.34
CDK4 P11802 1/20 0.34
CCNB1 P14635 1/20 0.34
CCND1 P24385 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
CCNB3 Q8WWL7 1/20 0.34
MAPT P10636 2/20 0.34
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71518 0.77 NPSR1 (0.59) L3MBTL1NPSR1KDM4EALDH1A1MAPT
SCHEMBL19139799 0.76 TSHR (0.38) L3MBTL1NPSR1KDM4EALDH1A1LMNA
SCHEMBL15197855 0.75 CTNNB1 (0.41) L3MBTL1KDM4EALDH1A1LMNAMAPT
SCHEMBL1761087 0.74 L3MBTL1 (0.38) L3MBTL1ATRNPSR1KDM4EALDH1A1
SCHEMBL24661304 0.74 OPRK1 (0.38)
SCHEMBL270591 0.74 L3MBTL1 (0.33) L3MBTL1ATRNPSR1KDM4EALDH1A1
SCHEMBL5159978 0.73 P2RX7 (0.41) L3MBTL1KDM4EALDH1A1CCNB2CCNE2
SCHEMBL5207248 0.72 L3MBTL1 (0.39) L3MBTL1ATRNPSR1KDM4EALDH1A1
SCHEMBL14740765 0.72 KDM4E (0.48) KDM4EMAPT
SCHEMBL9632764 0.72 NPSR1 (0.52) L3MBTL1NPSR1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180907-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2024-06-06 US disclosed
US-11730737-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-22 US disclosed
US-11730737-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-22 US disclosed
EP-4124620-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2023-02-01 EP disclosed
US-11529349-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-12-20 US disclosed
EP-3597650-B1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF UNIV COLUMBIA (US) 2022-09-07 EP disclosed
US-20200289512-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2020-09-17 US disclosed
US-20200268755-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-08-27 US disclosed
US-10639306-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-05 US disclosed
EP-3192796-B1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF UNIV COLUMBIA (US) 2019-09-04 EP disclosed
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-12 US disclosed
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-12 US disclosed
US-8916563-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-12-23 US disclosed
US-8916563-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-12-23 US disclosed
WO-2014113380-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-07-24 WO disclosed
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-29 US disclosed
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-29 US disclosed
EP-2593456-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2013-05-22 EP disclosed
CN-103052637-A Aldose reductase inhibitors and uses thereof UNIV COLUMBIA 2013-04-17 CN disclosed
WO-2012009553-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180907-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885
US-20200268755-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885
US-20200289512-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885
US-11529349-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885
US-10639306-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885
US-11730737-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 L3MBTL1 1660/4885ATR 3996/4885NPSR1 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.